• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Lupron Depot (leuprolide acetate for depot suspension), 11.25 mg, Lupron Depot (leuprolide acetate for depot suspension), 3.75 mg

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) 

 

July 2013

Summary View

WARNINGS AND PRECAUTIONS

Convulsions
  • Postmarketing reports of convulsions have been observed in patients on leuprolide acetate therapy. These included patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs. Convulsions have also been reported in patients in the absence of any of the conditions mentioned above. Patients receiving a GnRH agonist who experience convulsion should be managed according to current clinical practice.

ADVERSE REACTIONS

Postmarketing Experience
  • Hepato-biliary disorder: Serious drug-induced liver injury 

 

July 2012

Summary View

ADVERSE REACTIONS

Postmarketing
  • Respiratory, thoracic and mediastinal disorder – Interstitial lung disease

 

January 2012 

Summary View

ADVERSE REACTIONS

Postmarketing

Hepato-biliary disorder

  • rarely reported serious liver injury